KMPH - KemPharm, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.8000
-0.0300 (-1.06%)
As of 2:54PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close2.8300
Open2.8100
Bid2.830 x 1100
Ask2.840 x 900
Day's Range2.6500 - 2.8800
52 Week Range2.0010 - 8.4000
Volume186,670
Avg. Volume318,995
Market Cap74.075M
Beta (3Y Monthly)2.86
PE Ratio (TTM)N/A
EPS (TTM)-4.068
Earnings DateAug 8, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.58
Trade prices are not sourced from all markets
  • PR Newswire6 days ago

    Live Investor Conference & Webinar: NYSE, NASDAQ, and OTC companies present December 6th

    Company executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , Dec. 4, 2018 /PRNewswire/ -- PR Newswire and BetterInvesting (NAIC) today announced the agenda for the ...

  • PR Newswire7 days ago

    KemPharm to Webcast Live at VirtualInvestorConferences.com on December 6th

    CELEBRATION, Fla., Dec. 3, 2018 /PRNewswire/ -- KemPharm, Inc. (KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its President and CEO, Travis Mickle, Ph.D., will present live at VirtualInvestorConferences.com on December 6, 2018.

  • What Kind Of Shareholders Own KemPharm Inc (NASDAQ:KMPH)?
    Simply Wall St.14 days ago

    What Kind Of Shareholders Own KemPharm Inc (NASDAQ:KMPH)?

    A look at the shareholders of KemPharm Inc (NASDAQ:KMPH) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge companies Read More...

  • GlobeNewswire19 days ago

    Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Thomson Reuters StreetEvents20 days ago

    Edited Transcript of KMPH earnings conference call or presentation 8-Nov-18 9:30pm GMT

    Q3 2018 KemPharm Inc Earnings Call

  • GlobeNewswire27 days ago

    KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder

    KemPharm, Inc. (KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced the addition of a new product candidate, KP879, which the company plans to develop as an extended-duration, agonist replacement therapy for the treatment of Stimulant Use Disorder (SUD). Based on current timelines, KemPharm expects to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for KP879 as early as the end of 2018.

  • GlobeNewswirelast month

    KemPharm, Inc. Reports Third Quarter 2018 Results

    Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development Highlights: Announced positive topline results from KP415.E01.

  • GlobeNewswirelast month

    KemPharm to Report Third Quarter 2018 Results

    Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, November 8, 2018, 4:30 p.m. ET CORALVILLE, Iowa, Nov. 01, 2018 -- KemPharm, Inc..

  • GlobeNewswirelast month

    KemPharm Enters Into License Agreement with KVK Tech for the Commercialization of APADAZ®

    KemPharm, Inc. (KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs today announced its entry into a definitive collaboration and license agreement with KVK Tech, Inc. for the U.S. commercial rights of its FDA-approved prodrug product, APADAZ (benzhydrocodone and acetaminophen tablets). Under the terms of the agreement, KemPharm is eligible to receive up to an estimated $3.4 million in pre-launch payments and certain cost reimbursements, including a $2.0 million payment upon achievement of a specified milestone related to the initial formulary adoption of APADAZ, as well as an aggregate of up to $53 million in milestone payments tied to specific net sales levels.  In addition, net profits will be shared between KemPharm and KVK up to 50% based on achieving specified net sales levels.

  • GlobeNewswire2 months ago

    KemPharm Presents Data from Intranasal and Intravenous Human Abuse Potential Trials of KP415 Prodrug at the American Academy of Child & Adolescent Psychiatry Meeting

    CORALVILLE, Iowa, Oct. 24, 2018 -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today.

  • GlobeNewswire2 months ago

    KemPharm and twoXAR Announce Technology Collaboration to Develop Prodrug-Based Therapies for Multiple Indications

    Drug Development Approach Combines twoXAR’s Artificial-Intelligence-Driven Drug Discovery Technology with KemPharm’s LATTM Prodrug Technology CORALVILLE, Iowa, Oct. 23, 2018.

  • GlobeNewswire2 months ago

    KemPharm Provides Highlights from KOL Investor Event Focused on the ADHD Treatment Landscape

    Event Held Today, October 11, 2018 CORALVILLE, Iowa, Oct. 11, 2018 -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and.

  • MarketWatch2 months ago

    Aytu, KemPharm stocks plunge to pace Nasdaq decliners after share offerings

    Shares of Aytu BioScience Inc. plummeted 33% and of KemPharm Inc. plunged 32% Friday, to pace the Nasdaq's decliners, as both specialty pharmaceutical companies announced relatively large public share offerings that priced at deep discounts. KemPharm offered 8.33 million shares, representing 52% of the shares outstanding, that priced at $3.00 a share, or 28% below Thursday's closing price of $4.18. Meanwhile, Aytu offered 457,007 shares of common stock, 8.34 million shares of preferred stock convertible into 8.34 million shares of common stock at a conversion price of $1.50 per share, and warrants to buy and additional 8 million shares of common stock at an exercise price of $1.50 a share. That price was 26% below Thursday's closing price of $2.02. Aytu had 1.80 million shares outstanding as of Aug. 31. KemPharm shares have now lost 56% over the past three months and Aytu's stock has dropped 75%, while the S&P 500 has gained 6.1%.

  • GlobeNewswire2 months ago

    KemPharm Announces Proposed Public Offering of Common Stock

    KemPharm, Inc. (KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.  All of the shares of common stock to be sold in the offering will be offered by KemPharm.  In addition, KemPharm intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

  • GlobeNewswire2 months ago

    KemPharm to Host KOL Investor Event Focused on the ADHD Treatment Landscape

    Event to be Webcast Live on Thursday, October 11, 2018, at 8:30 a.m. ET CORALVILLE, Iowa, Oct. 03, 2018 -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company.

  • GlobeNewswire3 months ago

    KemPharm Announces Positive Topline Results from Intranasal Human Abuse Potential Trial of KP415 Prodrug

    KemPharm, Inc. (KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced topline results from its intranasal (IN) human abuse potential (HAP) clinical trial of serdexmethylphenidate (SDX, a prodrug of d-methylphenidate, or KP415 Prodrug), the major active pharmaceutical ingredient (API) in KP415, KemPharm’s investigational product candidate for the treatment of ADHD. In the IN HAP trial (KP415.A02), SDX produced significantly lower scores on the primary endpoint, maximal Drug Liking (Emax), and other abuse-related endpoints, compared to intranasal d-methylphenidate hydrochloride, indicating that SDX is not efficiently converted to active d-methylphenidate when snorted.

  • Zacks3 months ago

    KemPharm Posts Positive Top-Line Results on KP415 Prodrug

    KemPharm (KMPH) reports positive top-line results from second of three HAP studies on serdexmethylphenidate/KP415 Prodrug, which is contained in lead candidate KP415 that is being developed for ADHD.

  • Options Traders Expect Huge Moves in KemPharm (KMPH) Stock
    Zacks5 months ago

    Options Traders Expect Huge Moves in KemPharm (KMPH) Stock

    Investors in KemPharm (KMPH) need to pay close attention to the stock based on moves in the options market lately.

  • KemPharm Stock Down Despite Positive Data on ADHD Candidate
    Zacks5 months ago

    KemPharm Stock Down Despite Positive Data on ADHD Candidate

    KemPharm (KMPH) presents positive top-line results on ADHD candidate KP415, which meets both primary and secondary endpoints in a pivotal study.